Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:affects |
cell proliferation
cell survival |
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
melanoma |
| gptkbp:category |
targeted therapy
|
| gptkbp:combines |
gptkb:BRAF_inhibitors
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:discoveredIn |
2000s
|
| gptkbp:example |
gptkb:trametinib
gptkb:cobimetinib gptkb:refametinib gptkb:selumetinib gptkb:binimetinib |
| https://www.w3.org/2000/01/rdf-schema#label |
MEK inhibitors
|
| gptkbp:mechanismOfAction |
inhibit MAPK/ERK pathway
|
| gptkbp:metabolism |
liver
|
| gptkbp:sideEffect |
diarrhea
fatigue rash cardiotoxicity ocular toxicity |
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:MAPK/ERK_pathway
gptkb:RAS_gene |
| gptkbp:bfsLayer |
5
|